Calculate HOMA-IR, HOMA-B beta cell function, and QUICKI index from fasting insulin and glucose to assess insulin resistance severity.
The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) calculator is the most widely used surrogate marker for insulin resistance in clinical research and practice. Derived from fasting insulin and fasting glucose levels, HOMA-IR provides a simple, cost-effective estimate of insulin sensitivity that correlates well with the gold-standard euglycemic hyperinsulinemic clamp method (r ≈ 0.73).
Insulin resistance is the pathophysiologic hallmark of metabolic syndrome, type 2 diabetes, polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. Early identification through HOMA-IR allows intervention before these conditions fully develop—when lifestyle modifications and pharmacotherapy are most effective.
This calculator computes three complementary indices: HOMA-IR for insulin resistance, HOMA-%B for beta-cell function (insulin secretory capacity), and the QUICKI (Quantitative Insulin Sensitivity Check Index) for an alternative sensitivity measure. It also assesses metabolic syndrome risk factors and provides classification against population-based cutoff values. The combined display keeps the fasting labs and derived indices together so the relationship between glucose, insulin, and the calculated scores is easier to review. Check the example with realistic values before reporting.
HOMA-IR is easiest to interpret when the fasting insulin and glucose values are kept in the same frame of reference as the derived indices. This calculator groups the related measures together so the estimate of insulin resistance, beta-cell function, and QUICKI can be reviewed in one place without changing the underlying laboratory inputs or their basic clinical meaning.
HOMA-IR = (Fasting Insulin [μIU/mL] × Fasting Glucose [mg/dL]) / 405. HOMA-%B = (360 × Fasting Insulin) / (Fasting Glucose − 63). QUICKI = 1 / (log₁₀(Insulin) + log₁₀(Glucose)). Normal HOMA-IR < 2.0, insulin resistance typically ≥ 2.5-3.0.
Result: HOMA-IR: 2.81 — Early Insulin Resistance
Fasting insulin of 12 μIU/mL and glucose of 95 mg/dL yield HOMA-IR = (12 × 95) / 405 = 2.81, indicating early insulin resistance warranting lifestyle intervention.
Insulin resistance occurs when cells become less responsive to insulin, requiring the pancreas to produce more insulin to maintain normal blood glucose. This compensatory hyperinsulinemia maintains glucose homeostasis initially (normal glucose, high insulin), but as beta-cell function eventually declines, glucose levels rise through prediabetes to type 2 diabetes. HOMA-IR captures this spectrum by reflecting the insulin-glucose dynamic.
HOMA-IR has been extensively validated in diverse clinical settings. In PCOS, values ≥ 2.5 are associated with metabolic complications independent of obesity. In NAFLD, HOMA-IR correlates with liver fat content and fibrosis progression. In cardiovascular research, HOMA-IR independently predicts myocardial infarction and stroke risk. The metric is also valuable for monitoring response to interventions including metformin, thiazolidinediones, GLP-1 receptor agonists, and bariatric surgery.
HOMA-IR has important limitations: it assumes a feedback loop between liver and beta cells that may not hold in late-stage diabetes, it is less reliable in patients on insulin therapy, and insulin assay variability between laboratories limits absolute comparisons. The euglycemic hyperinsulinemic clamp remains the gold standard for research purposes but is impractical for clinical use. Other surrogate markers include QUICKI, the Matsuda index (from OGTT data), and the triglyceride-glucose index (TyG).
While cutoffs vary by population, HOMA-IR < 1.0 indicates optimal insulin sensitivity, 1.0-1.9 is normal, and values ≥ 2.5-3.0 are generally considered indicative of insulin resistance. Some populations use 1.9 or 2.0 as the threshold.
HOMA-%B estimates pancreatic beta-cell function—the ability of the pancreas to secrete insulin. Normal is approximately 100%. Values decline as beta-cell function deteriorates in the progression toward type 2 diabetes.
Both insulin and glucose must be measured in the fasting state (8-12 hours without food). Morning samples are preferred as insulin follows a diurnal pattern. Avoid exercise, stress, and caffeine before the draw.
HOMA-IR measures insulin resistance, not diabetes directly. However, high HOMA-IR combined with impaired fasting glucose or elevated HbA1c supports a prediabetes/diabetes diagnosis. Formal diagnosis follows ADA criteria (HbA1c ≥ 6.5%, FPG ≥ 126 mg/dL, etc.).
QUICKI (Quantitative Insulin Sensitivity Check Index) is an alternative insulin sensitivity measure calculated as 1 / (log(insulin) + log(glucose)). Values > 0.382 indicate normal sensitivity; < 0.339 suggests insulin resistance. QUICKI shows better linear correlation with clamp studies than HOMA-IR.
Evidence-based interventions include weight loss (5-10% body weight), regular exercise (150+ minutes/week of moderate activity), reduced refined carbohydrate intake, adequate sleep (7-9 hours), and medications like metformin when indicated. Use this as a practical reminder before finalizing the result.